Nasopharyngeal Carcinoma
Conditions
Brief summary
The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.
Detailed description
Enrolled patients with complete metabolic response (CMR) and more than 70% partial metabolic response (PMR) according to PERCIST criteria at the 25th fraction will receive intensity modulated radiation therapy (IMRT) of reduced-dose (prescribed dose, 63.6 Gy, 2.12 Gy per fractions, 30 fractions), for those who with ≤70% PMR will receive conventional dose (prescribed dose, 70Gy, 2.12 Gy per fractions, 33 fractions).
Interventions
RADIATIONReduced dose
The patients with CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
RADIATIONConventional dose
The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
DRUGChemotherapy
The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
Sponsors
Taizhou Enze Medical Center Group
Taizhou Cancer Hospital
Taizhou Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Pathology confirmed nasopharyngeal squamous cell carcinoma. 2. Stage I-IVA（8thAJCC/UICC staging system). 3. Aged 18-80 years. 4. KPS≥70. 5. Have measurable lesions on 18F-FDG PET/CT before treatment. 6. HGB≥90 g/L，ANC≥1.5×109 /L，PLT≥80×109 /L. 7. ALT,AST\<2.5 fold of ULN；TBIL\<2.0×ULN. 8. CCR≥60ml/min or Cr\<1.5×ULN. 9. Signed informed consent. 10. Have follow up condition.
Exclusion criteria
1. Past malignancies history (except for stage I non-melanoma skin cancer or cervical carcinoma in situ). 2. Age \<18 or \>80years. 3. Pregnancy or lactation. 4. History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume). 5. Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. 6. With sever infection and internal disease. 7. Major organ dysfunction, such as decompensated cardiopulmonary, kidney, liver failure, cannot tolerate surgical treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local-regional recurrence free survival (LRFS) | 5 years | The LRFS is evaluated and calculated from the date of initiation of treatment until the day of first locoregional relapse or until the date of the last follow-up visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | 5 years | Progress-free survival is calculated from the date of initiation of treatment to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up. |
| Distant metastasis-free survival (DMFS) | 5 years | The DMFS is evaluated and calculated from the date of initiation treatment until the day of first distant metastases or until the date of the last follow-up visit. |
| Incidence of treatment related acute complications | up to 3 months | treatment-related adverse events will be assessed by NCI-CTC5.0 criteria and RTOG/EORTC criteria. |
| Overall survival (OS) | 5 years | The OS was defined as the duration from the date of of initiation of treatment to the date of death from any cause or censored at the date of the last follow-up. |
| Overall response rate | up to 5 years | efficacy will be measured by PERCIST1.0 and RECIST1.1 criteria. |
| Incidence of treatment related late complications | up to 5 years | treatment-related adverse events will be assessed by NCI-CTC5.0 criteria and RTOG/EORTC criteria. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Biomarkers | up to 5 years | The correlation between the radiotherapy dose with biomarkers such as peripheral blood lymphocyte and EBV-DNA. |
Countries
China
Contacts
Primary ContactHaihua Yang, MD
Outcome results
None listed